Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pontus Lundberg

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Blood|July 23, 2020
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineagesRonny Nienhold, Peter Ashcroft, Jakub Zmajkovic, et al.
Nature|July 22, 2014
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasmsLorena Arranz, Abel Sánchez-Aguilera, Daniel Martín-Pérez, et al.
ACS Nano|December 24, 2015
Mussel-Inspired Anchoring of Polymer Loops That Provide Superior Surface Lubrication and Antifouling PropertiesTaegon Kang, Xavier Banquy, Jinhwa Heo, et al.
American Journal of Hematology|July 8, 2023
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm studyHui Liu, Linghui Xia, Jianyu Weng, et al.
European Journal of Haematology|June 15, 2023
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trialAlexander Röth, Satoshi Ichikawa, Yoshikazu Ito, et al.
British Journal of Clinical Pharmacology|January 21, 2025
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuriaValérie Cosson, Rong Fu, Austin Kulasekararaj, et al.
Haematologica|November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Blood|July 23, 2020
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineagesRonny Nienhold, Peter Ashcroft, Jakub Zmajkovic, et al.
Nature|July 22, 2014
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasmsLorena Arranz, Abel Sánchez-Aguilera, Daniel Martín-Pérez, et al.
ACS Nano|December 24, 2015
Mussel-Inspired Anchoring of Polymer Loops That Provide Superior Surface Lubrication and Antifouling PropertiesTaegon Kang, Xavier Banquy, Jinhwa Heo, et al.
American Journal of Hematology|July 8, 2023
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm studyHui Liu, Linghui Xia, Jianyu Weng, et al.
European Journal of Haematology|June 15, 2023
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trialAlexander Röth, Satoshi Ichikawa, Yoshikazu Ito, et al.
British Journal of Clinical Pharmacology|January 21, 2025
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuriaValérie Cosson, Rong Fu, Austin Kulasekararaj, et al.
Haematologica|November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Pageof 6